Malcolm has expertly covered the OTC drug and nutritional supplement industries and markets since 2006. He provides authoritative and highly analytical insight into how and why the US Food and Drug Administration regulates OTC drugs, including homeopathics, and nutritional supplement manufacturing and marketing and also how companies competing in these industries can most efficiently and effectively comply with FDA regulations, the cornerstone for their success.
Latest from Malcolm Spicer
Analysts hold back on predicting new heights for B+L until full split from parent firm. It reported Q4 revenue up 9% to $1.28bn and full-year revenue up 16% to $4.79bn.
Along with its 2024 full-year and fourth-quarter results – both down slightly – the Los Angeles-based firm on 19 February announced its board appointed Stephan Gratziani, president since January 2024, as CEO effective 1 May.
Jim Jones, the head of the FDA's food programs, resigned due to widespread layoffs at the agency imposed by the Trump administration’s Department of Government Efficiency.
As many as 700 employees reportedly dismissed from posts starting on 14 February as the culling of the federal workforce by the Trump administration’s Department of Government Efficiency reaches FDA.
Jim Jones resigna due to widespread layoffs at the agency the Trump administration’s Department of Government Efficiency imposed.
"While we mourn his passing, we also celebrate his remarkable legacy, which will continue to shape AHPA and the broader industry for years to come,” AHPA says.